Oman Pharmaceutical Products Co. LLC

Oman Pharmaceutical Products Co. LLC is a fully integrated healthcare company that develops, manufactures, and markets branded generic medicines in more than 40 markets. Established in 2001 to advance pharmaceutical expertise in Oman, the business combines research and development with regulatory research, production, testing, and distribution across the pharmaceutical value chain. Its commercial reach spans regulated markets, including the United States and the European Union; Gulf and Middle Eastern markets, such as Saudi Arabia, the United Arab Emirates, and Jordan; and markets across Africa and Asia. The company also develops and markets over-the-counter healthcare and hygiene products throughout the GCC.

Manufacturing is centered at its facility in Salalah, which has secured approvals from regulatory authorities including the US FDA, UK MHRA, Australia’s TGA, Brazil’s ANVISA, South Africa’s MCC, Korea’s MFDS, and GCC-DR. A global quality management system governs product development, manufacturing, testing, and distribution, with controls addressing internationally accepted standards for purity, efficacy, and safety. The operation forms part of Al Bahja Group, a diversified Omani conglomerate established in 1947 with activities across pharmaceuticals, agriculture, consumer goods, copper, real estate, hospitality, packaging, and alternative energy. This group foundation complements the pharmaceutical business’s international licensing, strategic alliances, and contract research and manufacturing activities.